关键信息
-
基因名
HLA-A*02:01&B2M&KRAS WT(KLVVVGAGGV) Monomer
- 应用
-
别名
HLA-A*0201 & B2M & KRAS (KLVVVGAGGV)
-
种属
Human
-
表达系统
HEK293
-
标签
C-Avi;C-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
AAA59606.1 (G25-I308)&P61769
-
表达区间
AAA59606.1 (G25-I308)&P61769 (I21-M119)&KLVVVGAGGV
-
分子量
40-45 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
质检流程
相关产品
背景信息
HLA-A*02:01 is one of the most prevalent major histocompatibility complex (MHC) class I molecules in the human population, playing a critical role in the presentation of antigens to CD8+ T cells, which is essential for initiating immune responses against tumors and infections. The study of HLA-A*02:01 in conjunction with beta-2-microglobulin (B2M) is vital, as B2M is essential for the stability and surface expression of MHC class I molecules, thus influencing T cell recognition. The KRAS gene is frequently mutated in various cancers, leading to active RAS protein and consequent malignant transformation. In particular, the wild-type (WT) KRAS peptide KLVVVGAGGV has been identified as a potential target for T cell-based immunotherapy in KRAS-driven tumors. By investigating the recombinant monomer of HLA-A*02:01, B2M, and KRAS WT peptide, researchers aim to enhance our understanding of T cell receptor (TCR) interactions and the underlying mechanisms of immune recognition. This knowledge is crucial for the development of therapeutic strategies, including cancer vaccines and adoptive T cell therapies, to effectively target tumors expressing KRAS WT peptides, ultimately improving clinical outcomes for patients with solid tumors. Understanding the structural and functional dynamics of this complex can lead to innovative approaches in cancer immunotherapy, maximizing the efficacy of anti-tumor immune responses.
